Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory tract congestion22.02.07.0030.006823%Not Available
Lymphatic disorder01.09.01.003--Not Available
Cardiac flutter02.03.02.0120.000964%Not Available
Epigastric discomfort07.01.02.0040.001640%Not Available
Musculoskeletal discomfort15.03.04.0010.002942%Not Available
Organ failure08.01.03.0410.000723%Not Available
Skin swelling23.03.03.0390.001640%Not Available
Dental discomfort07.09.06.0020.000820%Not Available
Cerebral disorder17.02.10.0170.002363%Not Available
Dysphemia19.19.03.005; 17.02.08.0100.001471%Not Available
Urine odour abnormal20.02.01.0200.002122%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.010802%Not Available
Chronic inflammatory demyelinating polyradiculoneuropathy17.09.04.004; 10.04.10.0040.000241%Not Available
Anxiety disorder19.06.01.0020.001230%Not Available
Cancer pain16.32.03.0040.000772%Not Available
Angiopathy24.03.02.0070.001013%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Ischaemic cerebral infarction24.04.06.013; 17.08.01.0220.000241%Not Available
Adverse event08.06.01.0100.041568%Not Available
Appetite disorder14.03.01.004; 19.09.01.0020.003110%Not Available
Bladder disorder20.03.01.0020.003834%Not Available
Breast disorder21.05.04.0040.001181%Not Available
Cardiac disorder02.11.01.0030.035661%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Diabetic complication14.07.03.002; 05.07.03.0020.000241%Not Available
Eyelid disorder23.03.03.028; 06.08.03.0100.000820%Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.004485%Not Available
Foetal disorder18.03.02.001--Not Available
Embolism24.01.01.009--
Gastrointestinal motility disorder07.02.03.0010.001640%Not Available
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 16 Pages